Information Provided By:
Fly News Breaks for November 7, 2019
Nov 7, 2019 | 06:31 EDT
JMP Securities analyst Donald Ellis lowered his price target on Aerie Pharmaceuticals to $41 after its Q3 earnings miss and a cut in FY19 revenue guidance, noting that Rocklatan's Medicare coverage uptake has been slower than expected and Rhopressa's average selling price has experienced pressure. The analyst is keeping his Outperform rating however, stating that while Aerie will have to generate about $16M to meet guidance for Q4, he sees that as highly likely since the underlying demand for Rocklatan is "strong."
News For AERI From the Last 2 Days
There are no results for your query AERI